Literature DB >> 24900178

Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.

Ashok Arasappan1, Frank Bennett1, Stephane L Bogen1, Srikanth Venkatraman1, Melissa Blackman1, Kevin X Chen1, Siska Hendrata1, Yuhua Huang1, Regina M Huelgas1, Latha Nair1, Angela I Padilla1, Weidong Pan1, Russell Pike1, Patrick Pinto1, Sumei Ruan1, Mousumi Sannigrahi1, Francisco Velazquez1, Bancha Vibulbhan1, Wanli Wu1, Weiying Yang1, Anil K Saksena1, Viyyoor Girijavallabhan1, Neng-Yang Shih1, Jianshe Kong1, Tao Meng1, Yan Jin1, Jesse Wong1, Paul McNamara1, Andrew Prongay1, Vincent Madison1, John J Piwinski1, Kuo-Chi Cheng1, Richard Morrison1, Bruce Malcolm1, Xiao Tong1, Robert Ralston1, F George Njoroge1.   

Abstract

Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37, with improved potency (∼10-fold over 1), pharmacokinetic profile and physicochemical characteristics, currently in phase II human trials. Exploration of synthetic sequence for preparation of 37 resulted in a route that required no silica gel purification for the entire synthesis.

Entities:  

Keywords:  Hepatitis C virus NS3 serine protease inhibitor; SCH 900518; narlaprevir; α-ketoamide

Year:  2010        PMID： 24900178      PMCID： PMC4007962          DOI： 10.1021/ml9000276

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


  19 in total

Review 1.  Replication of hepatitis C virus.

Authors:  R Bartenschlager; V Lohmann
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

2.  The scientific challenge of hepatitis C.

Authors:  J Cohen
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

Review 3.  A review of HCV protease inhibitors.

Authors:  Kevin X Chen; F George Njoroge
Journal:  Curr Opin Investig Drugs       Date:  2009-08

4.  Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.

Authors:  Srikanth Venkatraman; Stéphane L Bogen; Ashok Arasappan; Frank Bennett; Kevin Chen; Edwin Jao; Yi-Tsung Liu; Raymond Lovey; Siska Hendrata; Yuhua Huang; Weidong Pan; Tejal Parekh; Patrick Pinto; Veljko Popov; Russel Pike; Sumei Ruan; Bama Santhanam; Bancha Vibulbhan; Wanli Wu; Weiying Yang; Jianshe Kong; Xiang Liang; Jesse Wong; Rong Liu; Nancy Butkiewicz; Robert Chase; Andrea Hart; Sony Agrawal; Paul Ingravallo; John Pichardo; Rong Kong; Bahige Baroudy; Bruce Malcolm; Zhuyan Guo; Andrew Prongay; Vincent Madison; Lisa Broske; Xiaoming Cui; Kuo-Chi Cheng; Yunsheng Hsieh; Jean-Marc Brisson; Danial Prelusky; Walter Korfmacher; Ronald White; Susan Bogdanowich-Knipp; Anastasia Pavlovsky; Prudence Bradley; Anil K Saksena; Ashit Ganguly; John Piwinski; Viyyoor Girijavallabhan; F George Njoroge
Journal:  J Med Chem       Date:  2006-10-05       Impact factor: 7.446

5.  Emerging therapies for hepatitis C virus infection.

Authors:  B W Dymock
Journal:  Expert Opin Emerg Drugs       Date:  2001-04       Impact factor: 4.191

6.  Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).

Authors:  Scott D Seiwert; Steven W Andrews; Yutong Jiang; Vladimir Serebryany; Hua Tan; Karl Kossen; P T Ravi Rajagopalan; Shawn Misialek; Sarah K Stevens; Antitsa Stoycheva; Jin Hong; Sharlene R Lim; Xiaoli Qin; Robert Rieger; Kevin R Condroski; Hailong Zhang; Mary Geck Do; Christine Lemieux; Gary P Hingorani; Dylan P Hartley; John A Josey; Lin Pan; Leonid Beigelman; Lawrence M Blatt
Journal:  Antimicrob Agents Chemother       Date:  2008-09-29       Impact factor: 5.191

7.  MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.

Authors:  Nigel J Liverton; Steven S Carroll; Jillian Dimuzio; Christine Fandozzi; Donald J Graham; Daria Hazuda; M Katherine Holloway; Steven W Ludmerer; John A McCauley; Charles J McIntyre; David B Olsen; Michael T Rudd; Mark Stahlhut; Joseph P Vacca
Journal:  Antimicrob Agents Chemother       Date:  2009-10-19       Impact factor: 5.191

8.  Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.

Authors:  Srikanth Venkatraman; Mellissa Blackman; Wanli Wu; Latha Nair; Ashok Arasappan; Angela Padilla; Stéphane Bogen; Frank Bennett; Kevin Chen; John Pichardo; Xiao Tong; Andrew Prongay; Kuo-Chi Cheng; Viyyoor Girijavallabhan; F George Njoroge
Journal:  Bioorg Med Chem       Date:  2009-05-09       Impact factor: 3.641

9.  Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.

Authors:  V Lohmann; F Körner; J Koch; U Herian; L Theilmann; R Bartenschlager
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

10.  Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo.

Authors:  A A Kolykhalov; K Mihalik; S M Feinstone; C M Rice
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103
View more
  11 in total

1.  Small molecule pan-dengue and West Nile virus NS3 protease inhibitors.

Authors:  Lynne Cregar-Hernandez; Guan-Sheng Jiao; Alan T Johnson; Axel T Lehrer; Teri Ann S Wong; Stephen A Margosiak
Journal:  Antivir Chem Chemother       Date:  2011-05-12

2.  Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.

Authors:  X Tong; A Arasappan; F Bennett; R Chase; B Feld; Z Guo; A Hart; V Madison; B Malcolm; J Pichardo; A Prongay; R Ralston; A Skelton; E Xia; R Zhang; F G Njoroge
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 3.  The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry.

Authors:  Arun K Ghosh; Margherita Brindisi; Anindya Sarkar
Journal:  ChemMedChem       Date:  2018-10-11       Impact factor: 3.466

4.  Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.

Authors:  Lavanya Bondada; Ramu Rondla; Ugo Pradere; Peng Liu; Chengwei Li; Drew Bobeck; Tamara McBrayer; Philip Tharnish; Jerome Courcambeck; Philippe Halfon; Tony Whitaker; Franck Amblard; Steven J Coats; Raymond F Schinazi
Journal:  Bioorg Med Chem Lett       Date:  2013-09-30       Impact factor: 2.823

5.  Molecular and Dynamic Mechanism Underlying Drug Resistance in Genotype 3 Hepatitis C NS3/4A Protease.

Authors:  Djadé I Soumana; Nese Kurt Yilmaz; Akbar Ali; Kristina L Prachanronarong; Celia A Schiffer
Journal:  J Am Chem Soc       Date:  2016-09-02       Impact factor: 15.419

Review 6.  Development of novel antiviral therapies for hepatitis C virus.

Authors:  Kai Lin
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

7.  Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease.

Authors:  Daniel W Kneller; Hui Li; Gwyndalyn Phillips; Kevin L Weiss; Qiu Zhang; Mark A Arnould; Colleen B Jonsson; Surekha Surendranathan; Jyothi Parvathareddy; Matthew P Blakeley; Leighton Coates; John M Louis; Peter V Bonnesen; Andrey Kovalevsky
Journal:  Nat Commun       Date:  2022-04-27       Impact factor: 17.694

Review 8.  Current therapy for chronic hepatitis C: The role of direct-acting antivirals.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Antiviral Res       Date:  2017-02-24       Impact factor: 5.970

9.  Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease: room-temperature X-ray and neutron crystallography, binding thermodynamics, and antiviral activity.

Authors:  Daniel Kneller; Hui Li; Gwyndalyn Phillips; Kevin Weiss; Qiu Zhang; Mark Arnould; Colleen Jonsson; Surekha Surendranathan; Jyothi Parvathareddy; Matthew Blakeley; Leighton Coates; John Louis; Peter Bonnesen; Andrey Kovalevsky
Journal:  Res Sq       Date:  2022-02-11

10.  Identification of novel small molecules as inhibitors of hepatitis C virus by structure-based virtual screening.

Authors:  Jing Li; Xian Liu; Shanshan Li; Yulan Wang; Nannan Zhou; Cheng Luo; Xiaomin Luo; Mingyue Zheng; Hualiang Jiang; Kaixian Chen
Journal:  Int J Mol Sci       Date:  2013-11-20       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.